LPGO: Lipigon Pharmaceuticals AB (publ) - Summary | Jitta

Lipigon Pharmaceuticals AB (publ)

SWE:LPGO

Price
kr0.00
Loss Chance
58.3%
0.31JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
602 / 616
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (7)
Recent Business Performance (17)
Financial Strength (38)
Return to Shareholders (0)
Competitive Advantage (11)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Cash Conversion CycleLess than 60 days
Operating MarginInconsistent
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
0.31
100.00%
2.88
97.44%
2.88
97.44%
4.03
10.43%
1.89
100.00%
5.55
69.48%
COMPANY DESCRIPTION
Lipigon Pharmaceuticals AB (publ), a clinical-stage pharmaceutical company, develops drugs for lipid related diseases in Sweden. Its product pipeline consists of Lipisense project, which is in phase II for the treatment of severe hypertriglyceridemia disease; Dyslipidemia project, which is in preclinical trial to treat cardiovascular disease and severe hypertriglyceridemia; and CAP project, which is in preclinical trial to treat and prevent lung injury associated with community-acquired pneumonia. The company has a license agreement with Leaderna for the development of Lipisense. The company was incorporated in 2010 and is based in Umeå, Sweden.